Screener
Palvella Therapeutics PVLA Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Palvella Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.
The source filing: Palvella Therapeutics’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 8:30 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-210463
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| ASSETS | ||
| Current assets: | ||
| Cash and cash equivalents | $206,394 | $57,982 |
| Short-term investments | 55,459 | — |
| Prepaid expenses and other current assets | 1,378 | 1,005 |
| Total current assets | 263,231 | 58,987 |
| Operating lease right-of-use assets, net | 528 | 572 |
| Total assets | $263,759 | $59,559 |
Item 1. Financial Statements.
FAQ
- What is Palvella Therapeutics's cash & equivalents?
- Palvella Therapeutics (PVLA) reported cash & equivalents of $206.39M in Q1 2026.
- How has Palvella Therapeutics's cash & equivalents changed year-over-year?
- Palvella Therapeutics's cash & equivalents increased by 172.9% year-over-year, from $75.63M to $206.39M.
- What is the long-term trend for Palvella Therapeutics's cash & equivalents?
- Over 5 years (2020 to 2025), Palvella Therapeutics's cash & equivalents has grown at a -3.8% compound annual growth rate (CAGR), from $70.44M to $57.98M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.
Ask your AI about Palvella Therapeutics's cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude